顺铂联合吉西他滨或长春瑞滨治疗晚期乳腺癌的疗效分析

Analysis of Efficacy of Cisplatin Combined With Gemcitabine or Vinorelbine in the Treatment of Patients With Advanced Breast Cancer

目的探究顺铂联合吉西他滨与顺铂联合长春瑞滨治疗晚期乳腺癌的近期疗效和安全性。方法将来我院治疗的68例晚期乳腺癌患者随机分为两组,A组使用顺铂联合长春瑞滨治疗,B组患者使用顺铂联合吉西他滨治疗方式,回顾分析两组临床资料。结果 A组不良反应发生率为29.4%,B组为67.6%,A组低于B组(P<0.05)。结论顺铂联合吉西他滨与顺铂联合长春瑞滨治疗晚期乳腺癌效果显著,且顺铂联合长春瑞滨治疗的不良反应发生率较低。

Objective Short-term efficacy and safety of cisplatin combined with gemcitabine or vinorelbine in the treatment of patients with advanced breast cancer.Methods 68 cases of patients in our hospital were selected and randomly divided into group A and group B,patients in group A were treated with vinorelbine combined cisplatin,patients in group B were treated with gemcitabine combined with cisplatin,to analyze retrospectively the clinical data of two groups.Results The incidence rate of adverse reactions in group A was 29.4%,the incidence rate of adverse reactions in group B was 67.6%,which was significantly lower than 67.6% in group B with statistically significant differences（P〈0.05）.Conclusion Cisplatin combined with gemcitabine or vinorelbine have better clinical efficacy on the treatment of advanced breast cancer,while the application of cisplatin combined with vinorelbine has some advantage of less adverse reactions.